FemTech Startup Board Composition and Governance Norms

For FemTech startups, governance usually follows the venture-backed company pattern: founders first work with three board seats, a first independent director at about Series A, then a bigger and more independent setup at growth stage. But in FemTech, three sector-specific pressures squeeze that path out of shape, so founders should understand these dynamics ahead of any institutional term sheet.

Clinical validation is the first force. FemTech covers fertility through reproductive therapeutics, diagnostics, maternal care, and menopause, domains where clinical proof is not a pitch deck highlight but a requirement institutional capital sets prior to funding. Entrepreneurs here must generate such proof lacking the resources major drugmakers or veteran medtech players apply to identical challenges, while directors unable to gauge clinical risk cannot properly guide the choices most critical to keeping the business alive.

A second force emerges from the capital environment's sharp division into two tiers. Deal records indicate that the bulk of today's FemTech financings are modest in size, with a few exceptionally large rounds distorting the aggregate figures cited in news coverage, and Midi Health's biggest raise by itself represented an outsized portion of total sector investment during the latest tracked period. This two-tier divide has governance implications, since the standards designed for mature, capital-rich firms, independent board members, standing committees, and in-house legal teams, only fit a small fraction of the industry. The majority of FemTech ventures remain in seed or initial Series A stages for extended periods, handling clinical and regulatory decisions while operating with lean boards structured for far simpler operations. The distance separating governance budgets at the top from the lean boards elsewhere remains substantial, and growth alone will not close it; each stage must deliberately add that structure.

A third pressure point is that women have long been scarce in governance, even in a sector built mostly by women. MSCI reported in Women on Boards 2025 that, among the reviewed public companies in the large- and mid-cap categories, women occupied 28.3% of seats globally. Investor-backed private startups are excluded from that figure because their boards are determined each round by negotiated shareholder and investor-rights contracts, not public-company disclosure or listing regimes. Women start most young FemTech ventures, but in Jones Day's sector analysis, founding teams composed entirely of women received only a limited portion of overall VC dollars, while mixed-gender teams have taken in far more. The effect is predictable: the first non-founder board seat is often taken by a VC from a mostly male investment committee, someone who may have no personal or clinical connection to the product being built.

The standard governance playbook still has a place in FemTech. The playbook remains necessary, but it cannot carry the whole burden, so the sections that follow show the extra governance founders should build in at each stage.

Board Structure and Leverage

At venture-backed companies, legal documents establish Board composition: the investor rights agreements and shareholder agreements negotiated during each funding round, which allocate seats.

Three documents do the real work. The shareholder agreement assigns board seats directly, and its terms get revisited with each new funding round. Protective provisions list actions such as creating fresh shares, assuming liabilities, or greenlighting an acquisition that demand investor approval regardless of the director positions that backer controls. The required director count for board action comes from voting thresholds, while observer rights grant non-lead backers or occasional advisors access to meeting details without casting a ballot. Founders who view the term sheet solely as a fundraising instrument centered on price and ownership percentage overlook the embedded control framework, forfeiting bargaining power that later rounds rarely restore.

Across the sector, board seats tend to be arranged in a predictable way. At the seed stage, boards usually consist of two founders plus a single investor director. By Series A, companies commonly create a fifth seat for an independent director acceptable to founders and investors. With only three directors, the investor director is the sole non-founder in the room. That director sets early expectations for whether clinical claims are trusted, data is stewarded properly, and the mission stays aligned before any independent director joins to counterbalance the seat. An observer role, however, brings no ballot: if a clinical advisor or patient advocate occupies that place rather than a voting board seat, the company may hear more, but no one bears added responsibility, a crucial point in healthcare where clinical calls touch actual patients.

The same line applies across clinical advisory boards as a whole. Because advisors neither owe fiduciary duties nor vote, an impressive roster can still not replace a director able to press management on clinical strategy or the handling of data. When a founder builds advisory credibility yet keeps little domain expertise on the voting board, that may be a valuable asset, but it addresses a different issue from the one governance is meant to answer.

Strategic investors alter things in another way. A corporate venture arm with a board seat often imports an operating discipline a financial VC would not add alone: regulatory gates, requirements for clinical proof, and reimbursement targets woven into board routines. That is a real step up in what governance covers. Before taking that capital, founders should consider how far a lone strategic backer may steer board priorities.

Seed stage: getting the three-seat board right before the first investor takes a chair

The initial directors shape how every future group operates, and their usual blind spots, too many founders, little medical skill, no governance over patient records, are simpler to dodge early than fix after a VC joins.

Under the standard structure, founders get two board seats while the lead investor gets one, and that seat belongs to the fund leading the round, a decision the investor makes alone. Given that women make up the majority of FemTech founders while men dominate most investment committees, odds are the board's single outside voice represents a fund whose partners lack direct experience with the product, the condition it treats, or the patient reality the company serves. So the board's single outside viewpoint has no direct familiarity with the clinical risk the company must navigate.

Founders still hold leverage to shape terms now, prior to anyone filling the seat and locking in precedent. Because observer roles lack voting power, inviting a clinical advisor, someone representing the patient community, or a relevant specialist to attend enriches boardroom discussions well ahead of appointing any independent director. Founders must carefully examine the list of protective provisions detailing which moves demand investor approval, since neglecting that review could leave them facing a veto from an uninformed board member when pursuing clinical partnerships or data-sharing deals. A few go further at seed, securing a clause that unlocks an independent director position the moment the company reaches a set milestone such as filing with regulators or enrolling enough clinical trial participants, avoiding the need to let Series A dictate the timing.

Data governance needs a board seat immediately. Regulators have already targeted FemTech reproductive health data practices, including FTC action involving Flo and Premom, plus comparable health data enforcement involving BetterHelp and GoodRx. The enforcement record makes clear that poor data handling here can trigger actual regulatory penalties, not merely theoretical risk. Without a named director responsible for legal or privacy oversight at the seed stage, the board lacks a way to spot dangerous data practices before they turn into the company’s central liability.

A properly structured seed board frames investor participation as a governance choice, directly questioning the lead about their background in women's health ventures still in clinical trials, regulatory milestones, and data governance before signing the term sheet. Observer roles are deliberately assigned to incorporate medical or regulatory insight while keeping the formal headcount unchanged. It also codifies governance expectations into formal policy prior to any investor director joining, ensuring that clinical evidence benchmarks, privacy rules for data, and representation pledges remain fixed regardless of who occupies the seat.

Series A: when the independent director seat arrives

The outside board role usually added in a Series A round gives FemTech founders their most powerful governance choice, because it sits outside both founder and investor control. Founders can approach the decision with intention and room to shape it.

The setting where this decision happens has shifted. Recent funding figures reveal a noticeable drop in typical Series A sizes compared to the prior year, with startups taking longer to hit that milestone. Founders reach that critical juncture carrying heavier burdens and tighter timelines than conventional governance guidance anticipates, making the choice of an outside director all the more vital.

The role calls for a defined set of competencies. The independent director does not need to be a doctor, but the board does need at least one person able to assess the clinical record, the route through regulators, or the case for payment on the substance, work clinical advisory boards cannot handle because advisors owe no fiduciary obligations and are not accountable to the board. Today’s exposure tied to reproductive health data also makes this seat the right place for clear ownership of legal and data-governance duties inside the boardroom, a gap ordinary outside counsel cannot fill. The search should also track the investor network built around the field: Foreground Capital, formerly RH Capital, with Managing Partners Stasia Obremskey, Elizabeth Bailey, and Dr. Alice Zheng, who is co-founder and Partner, reflects sector-specific capital that now expects governance suited to FemTech’s clinical and regulatory demands, so founders seeking independent candidates need to understand the rest of that landscape.

Once the board grows to five seats, representation turns into a live variable. MSCI's 2025 report showed that close to half of large- and mid-cap public companies globally had achieved substantial female board representation, and studies released in 2026 indicate that governance quality strengthens when women hold enough seats to form a critical mass, not merely a symbolic presence. A five-seat FemTech board with a pair of investor positions and a pair of founder positions has a single undecided seat remaining: the independent one. When the founders are already women, adding a female independent director to that seat puts women in the majority of seats. But when a man occupies one of those investor or founder seats, the board risks missing the critical mass the research identifies as necessary for meaningful diversity effects. Founders ought to view the independent seat as their chance to secure a functional threshold, rather than settling for someone both factions merely accept.

The objection calls for a plain answer. In general, subject-matter expertise can matter more than demographics, and companies whose founders are men, including AngelEye Health and Inito, have succeeded for that reason. As a general rule, the objection is right. But in FemTech, women are disproportionately the people who know the care area clinically and have been its patients, making a single search for both traits the shortest route to the right board appointment.

Growth stage: building a majority-independent board that can support clinical scale and strategic capital

Once a company reaches the growth phase, who sits on the board has to mirror the difficulty of the choices ahead, from clinical evidence packages and strategic investor relationships to regulatory filings and data governance at real scale. Handling that work takes directors who have dealt with these problems firsthand, not generalists whose only experience is watching them unfold from across the table.

A company entering growth stage usually shifts to a board composed mainly of independent directors. Investor representatives stay on the board, yet surrender the decisive voting power they carried from earlier phases with fewer members and weightier individual votes. This broadening marks the stage where shortcomings in oversight from seed and Series A are either resolved or intensified. Should a board reach growth stage lacking clinical depth and legally accountable leadership, it faces maximum vulnerability precisely when oversight demands and payment pressures intensify.

Midi Health demonstrates how this approach works at scale, pairing clinical credibility with the concentrated capital discussed above to reach a size few peers have matched. Only a small set of companies can produce that result in any given window. That is why early governance design, from seed through Series A, carries such weight for everyone else. Founders who make board composition an intentional part of company architecture, rather than a side effect of the term sheet they accept, enter the growth stage with directors suited to the complexity ahead.